Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ® ) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the gr…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


